The β Fermi-Pasta-Ulam-Tsingou recurrence problem.

Chaos

Department of Physics, Boston University, Boston, Massachusetts 02215, USA.

Published: November 2019

We perform a thorough investigation of the first Fermi-Pasta-Ulam-Tsingou (FPUT) recurrence in the β-FPUT chain for both positive and negative β. We show numerically that the rescaled FPUT recurrence time T=t/(N+1) depends, for large N, only on the parameter S≡Eβ(N+1). Our numerics also reveal that for small |S|, T is linear in S with positive slope for both positive and negative β. For large |S|, T is proportional to |S| for both positive and negative β but with different multiplicative constants. We numerically study the continuum limit and find that the recurrence time closely follows the |S| scaling and can be interpreted in terms of solitons, as in the case of the KdV equation for the α chain. The difference in the multiplicative factors between positive and negative β arises from soliton-kink interactions that exist only in the negative β case. We complement our numerical results with analytical considerations in the nearly linear regime (small |S|) and in the highly nonlinear regime (large |S|). For the former, we extend previous results using a shifted-frequency perturbation theory and find a closed form for T that depends only on S. In the latter regime, we show that T∝|S| is predicted by the soliton theory in the continuum limit. We then investigate the existence of the FPUT recurrences and show that their disappearance surprisingly depends only on Eβ for large N, not S. Finally, we end by discussing the striking differences in the amount of energy mixing between positive and negative β and offer some remarks on the thermodynamic limit.

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.5122972DOI Listing

Publication Analysis

Top Keywords

positive negative
20
fput recurrence
8
recurrence time
8
small |s|
8
large |s|
8
continuum limit
8
positive
6
negative
6
|s|
6
fermi-pasta-ulam-tsingou recurrence
4

Similar Publications

Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.

Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.

View Article and Find Full Text PDF

Background: Memory is influenced by epigenetic mechanisms that regulate gene expression. Histone acetyltransferases (HATs), and histone deacetylases (HDACs), are two competitive enzymes regulating histone acetylation. Histone acetylation is reduced in Alzheimer's disease (AD) brains, and evidence has shown a synergistic regulation of HDACs and HATs activities.

View Article and Find Full Text PDF

Background: SHIP1 is a phosphatidyl inositol phosphatase encoded by INPP5D, which has been identified as a risk gene for Alzheimer's disease (AD). SHIP1 is expressed in microglia, the resident macrophage in brain. It is a complex, multidomain protein that acts as a negative regulator downstream from TREM2.

View Article and Find Full Text PDF

Background: Positive findings from testing therapeutics in AD animal models are often not translated to effective treatments due to the poor methodological rigor and inadequate reporting practices of therapeutic efficacy studies. The Alzheimer's Disease Preclinical Efficacy Database (AlzPED), developed by the NIA, is a searchable and publicly available knowledgebase that prioritizes and promotes the use of rigorous methodology to ameliorate this translation gap. Through a checklist of experimental design elements - the Rigor Report Card - AlzPED highlights reporting recommendations and standards while providing a practical tool to help plan rigorous therapeutic studies in animals.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

Background: Agitation is a common and disabling symptom of Alzheimer's dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!